Real-world effectiveness of mepolizumab in Japanese asthma patients with diverse backgrounds: Improvements in rhinosinusitis imaging (J-Real-Mepo)
Allergology International · 2025
DOI: 10.1016/j.alit.2024.12.005 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Allergology International, 2025. Verfasst von Hiroyuki Nagase und 25 weiteren Autor:innen. Beteiligte Einrichtung: Division of Respiratory Medicine and Allergology, Department of Medicine, Teikyo University School of Medicine, Tokyo, Japan; Teikyo Allergy Center, …. Hauptthemen laut MEDLINE: Asthma, Sinusitis, Antibodies, Monoclonal, Humanized, Rhinitis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: GlaxoSmithKline, GlaxoSmithKline KK.
Abstract (Originalsprache)
BACKGROUND: Although randomized controlled trials (RCT) have demonstrated the efficacy of mepolizumab for asthma, they have excluded certain patient subgroups. To bridge the gap between RCT and real-world practice, the effectiveness of mepolizumab in a diverse population, including those potentially excluded from RCT, was assessed. Its effects on imaging findings and symptoms of chronic rhinosinusitis (CRS) with asthma were also assessed. METHODS: This retrospective observational study of patients in Japan (J-Real-Mepo: UMIN000045021) evaluated multiple endpoints and analyzed the relationship between clinical background and treatment outcomes. RESULTS: Mepolizumab significantly reduced exacerbations, improved Asthma Control Test (ACT) scores, and forced expiratory volume in 1 s, and reduced oral corticosteroid (OCS) dose, regardless of patient characteristics, including age, body mass index, smoking history, and comorbidities. Regarding RCT exclusion criteria, 29.4 % of patients had no history of exacerbations. Although 25.4 % of these patients required continuous OCS, the OCS dose was reduced similar to those with a history of exacerbations. Disease control and mepolizumab effectiveness in patients with a smoking history ≥10 pack-years was similar to that of never-smokers. Patients with eosinophil counts
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Respiratory Medicine and Allergology, Department of Medicine, Teikyo University School of Medicine, Tokyo, Japan; Teikyo Allergy Center, Teikyo University Hospital, Tokyo, Japan. Electronic address: nagaseh@…
- Division of Respiratory Medicine and Allergology, Department of Medicine, Teikyo University School of Medicine, Tokyo, Japan; Teikyo Allergy Center, Teikyo University Hospital, Tokyo, Japan.
- Teikyo Allergy Center, Teikyo University Hospital, Tokyo, Japan; Department of Otolaryngology, Faculty of Medicine, Teikyo University, Tokyo, Japan.
- Clinical Research Center, National Hospital Organization Tokyo National Hospital, Tokyo, Japan.
- Department of Respiratory Medicine, Juntendo University Faculty of Medicine and Graduate School of Medicine, Tokyo, Japan.
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.
Förderung
- GlaxoSmithKline
- GlaxoSmithKline KK
Zitieren
APA
Nagase, H., Kobayashi, K., Toma-Hirano, M., Suzukawa, M., Harada, N., Masaki, K., Miyata, Y., Tsuji, M., Terada-Hirashima, J., Komatsuzaki, K., Sasano, H., Mizumura, K., Kagoya, R., Shimizu, Y., Yoshihara, S., Kihara, N., Miyazaki, Y., Koya, T., Sugihara, N., …, & J-Real-Mepo Investigators (2025). Real-world effectiveness of mepolizumab in Japanese asthma patients with diverse backgrounds: Improvements in rhinosinusitis imaging (J-Real-Mepo). Allergology International. https://doi.org/10.1016/j.alit.2024.12.005
Vancouver
Nagase H, Kobayashi K, Toma-Hirano M, Suzukawa M, Harada N, Masaki K, et al. Real-world effectiveness of mepolizumab in Japanese asthma patients with diverse backgrounds: Improvements in rhinosinusitis imaging (J-Real-Mepo). Allergology International. 2025. doi:10.1016/j.alit.2024.12.005
BibTeX
@article{Nagase2025,
author = {Nagase, Hiroyuki and Kobayashi, Konomi and Toma-Hirano, Makiko and Suzukawa, Maho and Harada, Norihiro and Masaki, Katsunori and Miyata, Yoshito and Tsuji, Mayoko and Terada-Hirashima, Junko and Komatsuzaki, Keiko and Sasano, Hitoshi and Mizumura, Kenji and Kagoya, Ryoji and Shimizu, Yuya and Yoshihara, Shintaro and Kihara, Norio and Miyazaki, Yasunari and Koya, Toshiyuki and Sugihara, Naruhiko and Ishikawa, Nobuhisa and Hojo, Masayuki and Tagaya, Etsuko and Tanaka, Akihiko and Fukunaga, Koichi and Gon, Yasuhiro and J-Real-Mepo Investigators, J-Real-Mepo Investigators},
title = {Real-world effectiveness of mepolizumab in Japanese asthma patients with diverse backgrounds: Improvements in rhinosinusitis imaging (J-Real-Mepo)},
journal = {Allergology International},
year = {2025},
doi = {10.1016/j.alit.2024.12.005}
}
EUVIMED